The use of azoles, a major class of antifungal drugs with fungistatic effects, to treat pathogenic fungi often results in the development of resistance, currently a serious problem in antifungal therapy. Azole antifungal drugs, many of which are approved for clinical use, are relatively inexpensive, share similar chemical structures, and are effective against most fungal species. Azoles target a crucial enzyme in the ergosterol biosynthesis pathway, whose inhibition leads to reduced growth. Azoles, combined with the host's immune system, result in the elimination of the fungus from the host. Since azoles do not kill fungal cells, their prolonged use and abuse often result in the development of resistance. The main mechanisms by which fungi become resistant are increased efflux of azole drugs and modifications in the sterol biosynthesis pathway, especially in the target enzyme. In general, all known fungal pathogens share these two basic types of resistance mechanism, although the specific efflux pumps, or mutations in sterol biogenesis, may be specific for each fungus. This chapter summarizes the main pathways in the development of azole resistance in the major human fungal pathogen, Candida albicans, and compares these mechanisms to those in other fungal pathogens. Resistance to other non-azole antifungal drugs is also discussed.